Press Releases - Renalytix

Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

03.15.21

NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provides an update

Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights

03.04.21

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that

RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021

03.02.21

NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance

The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health

02.24.21

Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease NEW YORK and SALT LAKE CITY, Feb.

RenalytixAI to announce Financial Results for six and three months ended December 31, 2020

02.23.21

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance

American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health

02.04.21

Event Featuring Leading Clinicians, Biotech Innovators and Federal Health Agencies to Highlight Innovation and Opportunity in Kidney Health NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company,

Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

01.13.21

Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway ( RIN:

Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

01.05.21

First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX)

RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference

01.04.21

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the

RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021

11.25.20

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported